Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Completed 2Terminated 1Recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Recurrence 1Neoplasms 1Colorectal Neoplasms 1Adenoma 1

Interventions

Cyclophosphamide 741Cisplatin 688Gemcitabine 641Bevacizumab 616Carboplatin 605Paclitaxel 601Docetaxel 565Radiotherapy 536Fluorouracil 405Oxaliplatin 387Rituximab 369Doxorubicin 361Capecitabine 342Filgrastim 333Etoposide 330Dexamethasone 312Irinotecan 309pembrolizumab 282Leucovorin 274Cetuximab 268Cytarabine 242Erlotinib Hydrochloride 231Nivolumab 228Prednisone 227Trastuzumab 225Vincristine 221Bortezomib 221Methotrexate 207Pemetrexed 199fludarabine phosphate 195

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Completed × Mesalamine × Clear all
NCT02077777 2016-12-02

Chemopreventive Action of Mesalazine on Colorectal Cancer: a Pilot Study for an "in Vivo" Evaluation of the Molecular Effects on β-catenin Signaling Pathway.

SOFAR S.p.A.

Phase 2 Completed
21 enrolled
Gastrointestinal

Neoplasms, Colorectal Neoplasms

NCT01894685 2015-12-08

Mesalazine Effects in Sporadic Colorectal Adenoma Patients

UMC Utrecht

Phase 2 Completed
74 enrolled

Adenoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡